7 results on '"Brouwers, Adrienne H."'
Search Results
2. Advances and challenges in immunoPET methodology.
- Author
-
Mohr, Philipp, van Sluis, Joyce, Hooge, Marjolijn N. Lub-de, Lammertsma, Adriaan A., Brouwers, Adrienne H., and Tsoumpas, Charalampos
- Subjects
DIAGNOSTIC imaging ,COMPUTER-assisted image analysis (Medicine) ,IMMUNOTHERAPY ,DYNAMICS ,POSITRON emission tomography ,POSITRON emission tomography computed tomography ,RADIOISOTOPES ,MONOCLONAL antibodies ,METALS ,DRUG development ,MOLECULAR diagnosis - Abstract
Immuno-positron emission tomography (immunoPET) enables imaging of specific targets that play a role in targeted therapy and immunotherapy, such as antigens on cell membranes, targets in the disease microenvironment, or immune cells. The most common immunoPET applications use a monoclonal antibody labeled with a relatively long-lived positron emitter such as 89Zr (T1/2= 78.4 h), but smaller antibody-based constructs labeled with various other positron emitting radionuclides are also being investigated. This molecular imaging technique can thus guide the development of new drugs and may have a pivotal role in selecting patients for a particular therapy. In early phase immunoPET trials, multiple imaging time points are used to examine the time-dependent biodistribution and to determine the optimal imaging time point, which may be several days after tracer injection due to the slow kinetics of larger molecules. Once this has been established, usually only one static scan is performed and semi-quantitative values are reported. However, total PET uptake of a tracer is the sum of specific and nonspecific uptake. In addition, uptake may be affected by other factors such as perfusion, pre-/co-administration of the unlabeled molecule, and the treatment schedule. This article reviews imaging methodologies used in immunoPET studies and is divided into two parts. The first part summarizes the vast majority of clinical immunoPET studies applying semi-quantitative methodologies. The second part focuses on a handful of studies applying pharmacokinetic models and includes preclinical and simulation studies. Finally, the potential and challenges of immunoPET quantification methodologies are discussed within the context of the recent technological advancements provided by long axial field of view PET/CT scanners. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial)
- Author
-
Mileva, Magdalena, primary, de Vries, Elisabeth G. E., additional, Guiot, Thomas, additional, Wimana, Zéna, additional, Deleu, Anne-Leen, additional, Schröder, Carolien P., additional, Lefebvre, Yolene, additional, Paesmans, Marianne, additional, Stroobants, Sigrid, additional, Huizing, Manon, additional, Aftimos, Philippe, additional, Tol, Jolien, additional, Van der Graaf, Winette T. A., additional, Oyen, Wim J. G., additional, Vugts, Danielle J., additional, Menke-van der Houven van Oordt, C. Willemien, additional, Brouwers, Adrienne H., additional, Piccart-Gebhart, Martine, additional, Flamen, Patrick, additional, and Gebhart, Géraldine, additional
- Published
- 2024
- Full Text
- View/download PDF
4. Head-to-head comparison of [11C]methionine PET, [11C]choline PET, and 4-dimensional CT as second-line scans for detection of parathyroid adenomas in primary hyperparathyroidism.
- Author
-
Noltes, Milou E., Kruijff, Schelto, Appelman, Auke P. A., Jansen, Liesbeth, Zandee, Wouter T., Links, Thera P., van Hemel, Bettien M., Schouw, Hugo M., Dierckx, Rudi A. J. O., Francken, Anne Brecht, Kelder, Wendy, van der Hoorn, Anouk, and Brouwers, Adrienne H.
- Subjects
PARATHYROID glands ,POSITRON emission tomography ,COMPUTED tomography ,ADENOMA ,METHIONINE ,CHOLINE ,HYPERPARATHYROIDISM - Abstract
Purpose: Accurate preoperative localization is imperative to guide surgery in primary hyperparathyroidism (pHPT). It remains unclear which second-line imaging technique is most effective after negative first-line imaging. In this study, we compare the diagnostic effectiveness of [
11 C]methionine PET/CT, [11 C]choline PET/CT, and four dimensional (4D)-CT head-to-head in patients with pHPT, to explore which of these imaging techniques to use as a second-line scan. Methods: We conducted a powered, prospective, blinded cohort study in patients with biochemically proven pHPT and prior negative or discordant first-line imaging consisting of ultrasonography and99m Tc-sestamibi. All patients underwent [11 C]methionine PET/CT, [11 C]choline PET/CT, and 4D-CT. At first, all scans were interpreted by a nuclear medicine physician, and a radiologist who were blinded from patient data and all imaging results. Next, a non-blinded scan reading was performed. The scan results were correlated with surgical and histopathological findings. Serum calcium values at least 6 months after surgery were used as gold standard for curation of HPT. Results: A total of 32 patients were included in the study. With blinded evaluation, [11 C]choline PET/CT was positive in 28 patients (88%), [11 C]methionine PET/CT in 23 (72%), and 4D-CT in 15 patients (47%), respectively. In total, 30 patients have undergone surgery and 32 parathyroid lesions were histologically confirmed as parathyroid adenomas. Based on the blinded evaluation, lesion-based sensitivity of [11 C]choline PET/CT, [11 C]methionine PET/CT, and 4D-CT was respectively 85%, 67%, and 39%. The sensitivity of [11 C]choline PET/CT differed significantly from that of [11 C]methionine PET/CT and 4D-CT (p = 0.031 and p < 0.0005, respectively). Conclusion: In the setting of pHPT with negative first-line imaging, [11 C]choline PET/CT is superior to [11 C]methionine PET/CT and 4D-CT in localizing parathyroid adenomas, allowing correct localization in 85% of adenomas. Further studies are needed to determine cost–benefit and efficacy of these scans, including the timing of these scans as first- or second-line imaging techniques. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
5. Correlation between Histopathological Prognostic Tumor Characteristics and [ 18 F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer.
- Author
-
Boers, Jorianne, Eisses, Bertha, Zwager, Mieke C., van Geel, Jasper J. L., Bensch, Frederike, de Vries, Erik F. J., Hospers, Geke A. P., Glaudemans, Andor W. J. M., Brouwers, Adrienne H., den Dekker, Martijn A. M., Elias, Sjoerd G., Kuip, Evelien J. M., van Herpen, Carla M. L., Jager, Agnes, van der Veldt, Astrid A. M., Oprea-Lager, Daniela E., de Vries, Elisabeth G. E., van der Vegt, Bert, Menke-van der Houven van Oordt, Willemien C., and Schröder, Carolina P.
- Subjects
METASTATIC breast cancer ,LOBULAR carcinoma ,EPIDERMAL growth factor receptors ,METASTASIS ,HISTOPATHOLOGY ,POSITRON emission tomography - Abstract
Background: In metastatic breast cancer (MBC), [
18 F]fluorodeoxyglucose positron emission tomography/computed tomography ([18 F]FDG-PET/CT) can be used for staging. We evaluated the correlation between BC histopathological characteristics and [18 F]FDG uptake in corresponding metastases. Patients and Methods: Patients with non-rapidly progressive MBC of all subtypes prospectively underwent a baseline histological metastasis biopsy and [18 F]FDG-PET. Biopsies were assessed for estrogen, progesterone, and human epidermal growth factor receptor 2 (ER, PR, HER2); Ki-67; and histological subtype. [18 F]FDG uptake was expressed as maximum standardized uptake value (SUVmax ) and results were expressed as geometric means. Results: Of 200 patients, 188 had evaluable metastasis biopsies, and 182 of these contained tumor. HER2 positivity and Ki-67 ≥ 20% were correlated with higher [18 F]FDG uptake (estimated geometric mean SUVmax 10.0 and 8.8, respectively; p = 0.0064 and p = 0.014). [18 F]FDG uptake was lowest in ER-positive/HER2-negative BC and highest in HER2-positive BC (geometric mean SUVmax 6.8 and 10.0, respectively; p = 0.0058). Although [18 F]FDG uptake was lower in invasive lobular carcinoma (n = 31) than invasive carcinoma NST (n = 146) (estimated geometric mean SUVmax 5.8 versus 7.8; p = 0.014), the metastasis detection rate was similar. Conclusions: [18 F]FDG-PET is a powerful tool to detect metastases, including invasive lobular carcinoma. Although BC histopathological characteristics are related to [18 F]FDG uptake, [18 F]FDG-PET and biopsy remain complementary in MBC staging (NCT01957332). [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
6. Ultra‐low dose CT scanning for PET/CT.
- Author
-
Mostafapour, Samaneh, Greuter, Marcel, van Snick, Johannes H., Brouwers, Adrienne H., Dierckx, Rudi A. J. O., van Sluis, Joyce, Lammertsma, Adriaan A., and Tsoumpas, Charalampos
- Subjects
POSITRON emission tomography computed tomography ,RADIATION exposure ,POSITRON emission tomography ,BODY mass index ,ELECTRON density ,COMPUTED tomography - Abstract
Background: The use of computed tomography (CT) for attenuation correction (AC) in whole‐body PET/CT can result in a significant contribution to radiation exposure. This can become a limiting factor for reducing considerably the overall radiation exposure of the patient when using the new long axial field of view (LAFOV) PET scanners. However, recent CT technology have introduced features such as the tin (Sn) filter, which can substantially reduce the CT radiation dose. Purpose: The purpose of this study was to investigate the ultra‐low dose CT for attenuation correction using the Sn filter together with other dose reduction options such as tube current (mAs) reduction. We explore the impact of dose reduction in the context of AC‐CT and how it affects PET image quality. Methods: The study evaluated a range of ultra‐low dose CT protocols using five physical phantoms that represented a broad collection of tissue electron densities. A long axial field of view (LAFOV) PET/CT scanner was used to scan all phantoms, applying various CT dose reduction parameters such as reducing tube current (mAs), increasing the pitch value, and applying the Sn filter. The effective dose resulting from the CT scans was determined using the CTDIVol reported by the scanner. Several voxel‐based and volumes of interest (VOI)‐based comparisons were performed to compare the ultra‐low dose CT images, the generated attenuation maps, and corresponding PET images against those images acquired with the standard low dose CT protocol. Finally, two patient datasets were acquired using one of the suggested ultra‐low dose CT settings. Results: By incorporating the Sn filter and adjusting mAs to the lowest available value, the radiation dose in CT images of PBU‐60 phantom was significantly reduced; resulting in an effective dose of nearly 2% compared to the routine low dose CT protocols currently in clinical use. The assessment of PET images using VOI and voxel‐based comparisons indicated relative differences (RD%) of under 6% for mean activity concentration (AC) in the torso phantom and patient dataset and under 8% for a source point in the CIRS phantom. The maximum RD% value of AC was 14% for the point source in the CIRS phantom. Increasing the tube current from 6 mAs to 30 mAs in patients with high BMI, or with arms down, can suppress the photon starvation artifact, whilst still preserving a dose reduction of 90%. Conclusions: Introducing a Sn filter in CT imaging lowers radiation dose by more than 90%. This reduction has minimal effect on PET image quantification at least for patients without Body Mass Index (BMI) higher than 30. Notably, this study results need validation using a larger clinical PET/CT dataset in the future, including patients with higher BMI. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. [A rapidly enlarging neck mass].
- Author
-
Lin JF, Links TP, Broekman KE, van Hemel B, Vister J, Verbeek HHG, Brouwers AH, and Kruijff S
- Subjects
- Humans, Diagnosis, Differential, Male, Female, Thyroid Carcinoma, Anaplastic pathology, Thyroid Carcinoma, Anaplastic diagnosis, Aged, Middle Aged, Head and Neck Neoplasms diagnosis, Head and Neck Neoplasms pathology, Neck pathology, Thyroid Neoplasms pathology, Thyroid Neoplasms diagnosis
- Abstract
The differential diagnosis of a rapidly enlarging neck mass consists of many different benign ((haemorrhagic) cyst) and malignant (anaplastic thyroid cancer (ATC) and lymphoma) causes. ATC is a rare disease with a median survival of 6 months. As early diagnosis and management are key for fast-growing cancers, in our centre we have implemented a dedicated short-stay in-hospital fast-track diagnostic work-up for patients with a rapid growing mass in the neck. The goal of this track is to have a fast diagnostic and therapeutic plan for this disease. Based on three clinical cases we discuss our experience with this fast-track diagnostic work-up for rapidly growing mass in the neck and illustrate the additional value in this clinical entity.
- Published
- 2024
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.